Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 4 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Cyclin-Dependent Kinase 2 (p33 Protein Kinase or cdc2-Related Protein Kinase or EC 2.7.11.22) Overview | 7 | 1 |
| Therapeutics Development | 8 | 4 |
| Cyclin-Dependent Kinase 2 (p33 Protein Kinase or cdc2-Related Protein Kinase or EC 2.7.11.22) Products under Development by Stage of Development | 8 | 1 |
| Cyclin-Dependent Kinase 2 (p33 Protein Kinase or cdc2-Related Protein Kinase or EC 2.7.11.22) Products under Development by Therapy Area | 9 | 1 |
| Cyclin-Dependent Kinase 2 (p33 Protein Kinase or cdc2-Related Protein Kinase or EC 2.7.11.22) Products under Development by Indication | 10 | 2 |
| Cyclin-Dependent Kinase 2 (p33 Protein Kinase or cdc2-Related Protein Kinase or EC 2.7.11.22) Pipeline Products Glance | 12 | 2 |
| Late Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Cyclin-Dependent Kinase 2 (p33 Protein Kinase or cdc2-Related Protein Kinase or EC 2.7.11.22) Products under Development by Companies | 14 | 3 |
| Cyclin-Dependent Kinase 2 (p33 Protein Kinase or cdc2-Related Protein Kinase or EC 2.7.11.22) Products under Development by Universities/Institutes | 17 | 2 |
| Cyclin-Dependent Kinase 2 (p33 Protein Kinase or cdc2-Related Protein Kinase or EC 2.7.11.22) Therapeutics Assessment | 19 | 5 |
| Assessment by Monotherapy/Combination Products | 19 | 1 |
| Assessment by Mechanism of Action | 20 | 1 |
| Assessment by Route of Administration | 21 | 2 |
| Assessment by Molecule Type | 23 | 1 |
| Cyclin-Dependent Kinase 2 (p33 Protein Kinase or cdc2-Related Protein Kinase or EC 2.7.11.22) Companies Involved in Therapeutics Development | 24 | 4 |
| Astex Pharmaceuticals, Inc. | 24 | 1 |
| Cyclacel Pharmaceuticals, Inc. | 25 | 1 |
| Tiziana Life Sciences Plc | 26 | 1 |
| Tragara Pharmaceuticals, Inc. | 27 | 1 |
| Cyclin-Dependent Kinase 2 (p33 Protein Kinase or cdc2-Related Protein Kinase or EC 2.7.11.22) Drug Profiles | 28 | 20 |
| AT-7519 Drug Profile | 28 | 3 |
| CCT-68127 Drug Profile | 31 | 1 |
| CYC-065 Drug Profile | 32 | 3 |
| JRP-890 Drug Profile | 35 | 1 |
| milciclib Drug Profile | 36 | 2 |
| sapacitabine + seliciclib Drug Profile | 38 | 3 |
| seliciclib Drug Profile | 41 | 2 |
| Small Molecule to Inhibit CDK2 for Oncology Drug Profile | 43 | 1 |
| Small Molecules to Inhibit CDK2 for Oncology Drug Profile | 44 | 1 |
| TG-02 Drug Profile | 45 | 3 |
| Cyclin-Dependent Kinase 2 (p33 Protein Kinase or cdc2-Related Protein Kinase or EC 2.7.11.22) Dormant Projects | 48 | 2 |
| Cyclin-Dependent Kinase 2 (p33 Protein Kinase or cdc2-Related Protein Kinase or EC 2.7.11.22) Discontinued Products | 50 | 1 |
| Cyclin-Dependent Kinase 2 (p33 Protein Kinase or cdc2-Related Protein Kinase or EC 2.7.11.22) Featured News &Press Releases | 51 | 13 |
| Jun 06, 2016: Cyclacel Reports Updated Data From Its DNA Damage Response Program on Seliciclib and Sapacitabine Combination in Patients With Solid Tumors at ASCO | 51 | 2 |
| May 19, 2016: Cyclacel s Seliciclib-Sapacitabine Abstract Selected for Oral Presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting | 53 | 1 |
| Apr 18, 2016: Cyclacel s Second-Generation CDK2/9 Inhibitor, CYC065, is an Effective Inducer of Cell Death in B-cell Lymphoma and Synergizes With Bcl-2 or BET Inhibitors | 53 | 1 |
| Dec 14, 2015: Molecular Basis for Development of Cyclacel s CYC065 CDK2/9 Inhibitor in Triple-Negative Breast Cancer Presented at San Antonio Breast Cancer Symposium | 54 | 1 |
| Nov 23, 2015: CYC065, Cyclacel's Novel CDK2/9 Inhibitor, Prolongs Survival in MYCN-Addicted Neuroblastoma Models | 55 | 1 |
| Nov 09, 2015: Mechanistic Rationale for CYC065, Cyclacel's CDK2/9 Inhibitor, in Targeted Solid Tumors and Hematological Malignancies Presented at AACR-NCI-EORTC International Conference | 56 | 1 |
| Oct 26, 2015: Data to be Presented on CYC065, Cyclacel's CDK2/9 Inhibitor, at AACR-NCI-EORTC International Conference | 57 | 1 |
| Oct 22, 2015: Cyclacel Doses First Patient in Phase 1 Trial of Its Novel CDK2/9 Inhibitor, CYC065, for the Treatment of Advanced Solid Tumors | 57 | 1 |
| Sep 17, 2015: Cyclacel Presents Molecular Rationale for Clinical Development of CYC065 CDK Inhibitor in Leukemias and Lymphomas | 58 | 1 |
| Jul 02, 2015: First Patient Dosed in IST of CDK Inhibitor Seliciclib in Cushing's Disease, a Serious Endocrine Disorder | 59 | 1 |
| Apr 20, 2015: Cyclacel's CDK2/9 Inhibitor, Seliciclib, Preclinical Data Presented at the AACR | 59 | 1 |
| Apr 20, 2015: Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Demonstrates Therapeutic Potential and Synergy With Other Anti-Cancer Compounds | 60 | 1 |
| Mar 20, 2015: Cyclacel's CYC065 Featured in Presentations at the American Association for Cancer Research Annual Meeting 2015 | 61 | 1 |
| Oct 28, 2014: Thymic carcinoma Phase II data of Milciclib, a kinase inhibitor discovered at Nerviano Medical Sciences, disclosed at the medical oncology meeting AIOM 2014 | 62 | 1 |
| Sep 18, 2014: Cyclacel's CYC065 CDK Inhibitor Demonstrates Therapeutic Potential in Acute Leukemias With Mixed Lineage Leukemia (MLL) Rearrangements | 62 | 2 |
| Appendix | 64 | 2 |
| Methodology | 64 | 1 |
| Coverage | 64 | 1 |
| Secondary Research | 64 | 1 |
| Primary Research | 64 | 1 |
| Expert Panel Validation | 64 | 1 |
| Contact Us | 64 | 1 |
| Disclaimer | 65 | 1 |